Current situation of the pandemic in Brazil: technological innovation, advances in Science and challenges
DOI:
https://doi.org/10.33448/rsd-v10i16.23493Keywords:
Brazil; Sience; Coronavirus; Tecnologic innovation.Abstract
The 2019 Coronavirus disease pandemic showed that the world was not sufficiently prepared to face emerging epidemics, exposing great global sanitary and socioeconomic vulnerability, especially in underdeveloped countries like Brazil, being the second country with the highest number of contagion rates and deaths, surpassing the 600 thousand deaths mark. The objective of this review is to identify drugs and vaccines in development and discuss the main challenges of the pandemic in Brazil. With the rapid advance of the pandemic, a technological race for the development of vaccines against the coronavirus began. There are currently more than 300 vaccines under development against COVID-19, among them 18 are being developed by Brazilian institutes. In addition, the emergency use of 4 candidate vaccines was approved, namely: Covisheield, Comirnaty, Coronavac and Janssen. The fight against the pandemic in Brazil comes up against obstacles such as lack of basic sanitation, limited access to health services and quality education, in addition to mistaken actions or omissions by the public authorities and the widespread dissemination of misinformation about the disease, which contributed to the an increase in the number of cases, and a weakening of the health system. Currently, the advance in vaccination of 58.25% of the adult population with a complete vaccination schedule has resulted in a consistent drop in cases and deaths, thanks to a solid state structure of a vaccination program with high capillarity and high popular acceptance of the vaccine.
References
Abi Younes, G., Ayoubi, C., Ballester, O., Cristelli, G., de Rassenfosse, G., Foray, D., Gaulé, P., Pellegrino, G., van den Heuvel, M., Webster, E., & Zhou, L. (2020). COVID-19: Insights from innovation economists. Science and Public Policy, 1–13. https://doi.org/10.1093/scipol/scaa028
Almeida, L. de S. B., Silveira, R. M. da C., Silva, B. C. do N., Queiroz, J. V. R. de, & Oliveira, P. H. C. do N. de. (2020). As universidades públicas brasileiras no contexto da pandemia: iniciativas e parcerias no enfrentamento da covid-19. Cadernos Gestão Pública e Cidadania, 25(82), 1–20. http://dx.doi.org/10.12660/cgpc.v25n82.82123
Aquino, E. M. L., Silveira, I. H., Pescarini, J. M., Aquino, R., & de Souza-Filho, J. A. (2020). Social distancing measures to control the COVID-19 pandemic: Potential impacts and challenges in Brazil. Ciencia e Saude Coletiva, 25, 2423–2446. https://doi.org/10.1590/1413-81232020256.1.10502020
Biasio, L. R., Bonaccorsi, G., Lorini, C., & Pecorelli, S. (2021). Assessing COVID-19 vaccine literacy: a preliminary online survey. Human Vaccines and
Immunotherapeutics, 17(5), 1304–1312. https://doi.org/10.1080/21645515.2020.1829315
Bliddal, S., Banasik, K., Pedersen, O. B., Nissen, J., Cantwell, L., Schwinn, M., Tulstrup, M., Westergaard, D., Ullum, H., Brunak, S., Tommerup, N., Feenstra, B., Geller, F., Ostrowski, S. R., Grønbæk, K., Nielsen, C. H., Nielsen, S. D., & Feldt-Rasmussen, U. (2021). Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. Scientific Reports, 11(1), 1–11. https://doi.org/10.1038/s41598-021-92045-x
Blomberg, B., Mohn, K. G.-I., Brokstad, K. A., Zhou, F., Linchausen, D. W., Hansen, B.-A., Lartey, S., Onyango, T. B., Kuwelker, K., Sævik, M., Bartsch, H., Tøndel, C., Kittang, B. R., Madsen, A., Bredholt, G., Vahokoski, J., Fjelltveit, E. B., Bansal, A., Trieu, M. C., & Langeland, N. (2021). Long COVID in a prospective cohort of home-isolated patients. Nature Medicine. https://doi.org/10.1038/s41591-021-01433-3
Bonadio, E., & Baldini, A. (2020). Covid-19, patents and the never-ending tension between proprietary rights and the protection of public health. European Journal of Risk Regulation, 11(2), 390–395. https://doi.org/10.1017/err.2020.24
Brasil. (2020). Relatório Técnico – Monitoramento de vacinas em desenvolvimento contra Sars-CoV-2. 30 de novembro de 2020. Ministério da Saúde. Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos Em Saúde. Departamento de Ciência e Tecnologia.
Brasil. (2020a). PORTARIA No 1.565, DE 18 DE JUNHO DE 2020. Estabelece orientações gerais visando à prevenção, ao controle e à mitigação da transmissão da COVID-19, e à promoção da saúde física e mental da população brasileira, de forma a contribuir com as ações para a re. Diário Oficial Da União. Brasilia. http://www.in.gov.br/en/web/dou/-/portaria-n-1.565-de-18-de-junho-de-2020-262408151
Brasil. (2020b). Portaria No 47, de 26 de março de 2020. Dispõe sobre a restrição excepcional e temporária de entrada no País de estrangeiros por transporte aquaviário, conforme recomendação da Agência Nacional de Vigilância Sanitária - Anvisa. Ministério da Saúde. Diário Oficial Da União. Brasilia.
Brito, J. C. M., Lima, W. G., Cardoso, B. G., Simião, D. C., Amorim, J. M., & Silva, C. de A. (2020). Uso irracional de medicamentos e plantas medicinais contra a COVID-19 (SARS-CoV-2): Um problema emergente. Brazilian Journal of Health and Pharmacy, 2(3), 37–53. https://doi.org/10.29327/226760.2.3-5
Brizzi, A., Whittaker, C., Servo, L., Hawryluk, I., Prete, C. A., de Souza, W. M., Aguiar, R. S., Araujo, L., Bastos, L. S., Blenkinsop, A., Buss, L. F., Candido, D., Castro, M. C., Costa, S. F., Croda, J., de Souza Santos, A. A., Dye, C., Flaxman, S., Fonseca, P., Geddes, V., … Ratmann, O. (2021). Report 46: Factors driving extensive spatial and temporal fluctuations in COVID-19 fatality rates in Brazilian hospitals. medRxiv : the preprint server for health sciences, 2021.11.01.21265731. https://doi.org/10.1101/2021.11.01.21265731
CONASS (2021). Conselho Nacional de Secretários de Saúde. Painel CONASS COVID-19. https://www.conass.org.br/painelconasscovid19/.
Contreras, J. L. (2020). Expandindo o acesso a patentes para COVID-19. 50.
Cox, R. M., Wolf, J. D., & Plemper, R. K. (2021). Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nature Microbiology, 6(1), 11–18. https://doi.org/10.1038/s41564-020-00835-2
de Oliveira, E. H. A. (2020). Coronavírus: prospecção científica e tecnlógica dos fármacos em estudo para tratamento da Covid-10. Cadernos de Prospecção, 13(2), 412–423. http://dx.doi.org/10.9771/cp.v13i2.COVID-19.36153
Ferreira, L. L. G., & Andricopulo, A. D. (2020). Medicamentos e tratamentos para a Covid-19. Estudos Avancados, 34(100), 7–27. https://doi.org/10.1590/s0103-4014.2020.34100.002
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., Dold, C., Faust, S. N., Finn, A., Flaxman, A. L., Hallis, B., Heath, P., Jenkin, D., Lazarus, R., Makinson, R., … Pollard, A. J. (n.d.). Articles Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 : a preliminary report of a phase 1 / 2 , single-blind , randomised controlled trial. 467–478.
Funk, C. D., Laferrière, C., & Ardakani, A. (2020). A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic. Frontiers in Pharmacology, 11(June), 1–17. https://doi.org/10.3389/fphar.2020.00937
Guimarães, R. (2020). Anti-covid vaccines: A look from the collective health. Ciencia e Saude Coletiva, 25(9), 3579–3585. https://doi.org/10.1590/1413-81232020259.24542020
Guimarães, V. H. A., de Oliveira-Leandro, M., Cassiano, C., Marques, A. L. P., Motta, C., Freitas-Silva, A. L., de Sousa, M. A. D., Silveira, L. A. M., Pardi, T. C., Gazotto, F. C., Silva, M. V., Rodrigues, V., Rodrigues, W. F., & Oliveira, C. J. F. (2021). Knowledge about COVID-19 in Brazil: Cross-sectional web-based study. JMIR Public Health and Surveillance, 7(1). https://doi.org/10.2196/24756
Hallal, P. C. (2021). SOS Brazil: science under attack. The Lancet, 397(10272), 373–374. https://doi.org/10.1016/S0140-6736(21)00141-0
Houvèssou, G. M., Souza, T. P. de, & Silveira, M. F. da. (2021). Medidas de contenção de tipo lockdown para prevenção e controle da COVID-19: estudo ecológico descritivo, com dados da África do Sul, Alemanha, Brasil, Espanha, Estados Unidos, Itália e Nova Zelândia, fevereiro a agosto de 2020. Epidemiologia e Servicos de Saude : Revista Do Sistema Unico de Saude Do Brasil, 30(1), e2020513. https://doi.org/10.1590/S1679-49742021000100025
Instituto Brasileiro de Geografia e Estatística - IBGE (2021). População do Brasil. https://www.ibge.gov.br/apps/populacao/projecao/box_popclock.php.
Kim, J. H., Marks, F., & Clemens, J. D. (2021). Looking beyond COVID-19 vaccine phase 3 trials. Nature Medicine, 27(2), 205–211. https://doi.org/10.1038/s41591-021-01230-y
Lima, E. J. da F., Almeida, A. M., & Ávila, R. de. (2021). Vacinas para COVID-19 - o estado da arte. Rev. Bras. Saúde Matern. Infant, 21, 21–27. http://dx.doi.org/10.1590/1806-9304202100S100002
Macedo, Y. M., Ornellas, J. L., & Bomfim, H. F. do. (2020). COVID – 19 NO BRASIL: o que se espera para população subalternizada? Revista Encantar, 1–10. https://doi.org/10.5935/encantar.v2.0001
Mahase, E. (2021). Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. Bmj, October, n2422. https://doi.org/10.1136/bmj.n2422
Ministério da saúde (MS). COVID-19 Painel Coronavírus. Brasília: MS; 2021. Disponível em: https://covid.saude.gov.br/ https://covid.saude.gov.br/. (2021). 2021.
Moreira, R. M., Villa Montoya, A. C., Silveria Araujo, S. L., Trindade, R. A., da Cunha Oliveira, D., & de Oliveira Marinho, G. (2020). How prepared is Brazil to tackle the COVID-19 disease? Journal of Global Health, 10(2), 020321. https://doi.org/10.7189/jogh.10.020321
Nalbandian, A., Sehgal, K., Gupta, A., Madhavan, M. V., McGroder, C., Stevens, J. S., Cook, J. R., Nordvig, A. S., Shalev, D., Sehrawat, T. S., Ahluwalia, N., Bikdeli, B., Dietz, D., Der-Nigoghossian, C., Liyanage-Don, N., Rosner, G. F., Bernstein, E. J., Mohan, S., Beckley, A. A., & Wan, E. Y. (2021). Post-acute COVID-19 syndrome. Nature Medicine, 27(4), 601–615. https://doi.org/10.1038/s41591-021-01283-z
Panizzon, M., Costa, C. F. da, & Medeiros, I. B. de O. (2020). Práticas das universidades federais no combate à COVID-19: a relação entre investimento público e capacidade de implementação. Revista de Administração Pública, 54(4), 635–649. https://doi.org/10.1590/0034-761220200378
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., & Gruber, W. C. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine, 383(27), 2603–2615. https://doi.org/10.1056/nejmoa2034577
Ritchie, H., Mathien, E., Rodés-Guirao, L., Appel, C., Giattino, C., Ortiz-Ospina, E., Hasell, J., Macdonald, B., Beltekian, D., & Roser, M. (2020) "Coronavirus Pandemic (COVID-19)".http://ourworldindata.org/coronavirus'
Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., Offergeld, K., Scheper, G., Taylor, K. L., Robb, M. L., Treanor, J., Barouch, D. H., Stoddard, J., Ryser, M. F., Marovich, M. A., & Douoguih, M. (2021). Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. New England Journal of Medicine, 384(23), 2187–2201. https://doi.org/10.1056/nejmoa2101544
Silva, F. C. da, Zamprogna, K. M., Souza, S. S. de, & Sell, D. H. S. D. (2021). Isolamento social e a velocidade de casos de covid-19: medida de prevenção da transmissão. Revista Gaucha de Enfermagem, 42, e20200238. https://www.seer.ufrgs.br/RevistaGauchadeEnfermagem/article/view/110513
Silva, K. M. R. da, Silva, P. B. da, Silva, H. J. N. da, Silva, P. T. da, Silva, B. L., Ferreira, A. M. C., Bezerra, W. A. dos S., Silva, D. de A. e, Campos, M. R. de, Oliveira, D. M. T. e, Nascimento, A. L. L. do, Ribeiro, A. M. de C., Silva, A. M. da, Sousa, E. A., Oliveira, I. K. F., Lopes, M. M. F., Andrade, N. B. de, Pinheiro, I. M., Ferreira, K. L. C., & Furtado, D. R. L. (2021). Avaliação dos principais fármacos utilizados para o sars-cov-2: uma prospecção cientifica e tecnológica. Research, Society and Development, 2021, 1–14. https://doi.org/10.33448/rsd-v10i3.13136
Van Overwalle, G. (2020). Will Covid Patents Save the World? GRUR International, 69(9), 883–884. https://doi.org/10.1093/grurint/ikaa110
Welison Matheus Fontes da Silva e Jefferson Lee de Souza Ruiz. (2020). Coronavírus E As Disputas Com O Projeto Neoliberal. 30(3), 1–8.
Werneck, G. L., & Carvalho, M. S. (2020). A pandemia de COVID-19 no Brasil: Crônica de uma crise sanitária anunciada. Cadernos de Saude Publica, 36(5), 1–4. https://doi.org/10.1590/0102-311X00068820
World Health Organization (2021a). COVID-19 vaccine tracker and landscape: Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
World Health Organization (2021). Painel do Coronavírus da OMS (COVID-19) https://covid19.who.int/.
Zambrano, V. (2020). O Direito À Saúde E À Vida Em Confronto Com O Direito À Propriedade Intelectual Dos Laboratórios , No Âmbito Da Pandemia Da Covid 19 : a Possivel Quebra De Patentes. 05, 168–192.
Zhang, J. jin, Dong, X., Cao, Y. yuan, Yuan, Y. dong, Yang, Y. bin, Yan, Y. qin, Akdis, C. A., & Gao, Y. dong. (2020). Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy: European Journal of Allergy and Clinical Immunology, 75(7), 1730–1741. https://doi.org/10.1111/all.14238
Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., Chen, X., Hu, Y., Liu, X., Jiang, C., Li, J., Yang, M., Song, Y., Wang, X., Gao, Q., & Zhu, F. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases, 21(2), 181–192. https://doi.org/10.1016/S1473-3099(20)30843-4
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Thaís Paula de Araújo; Luana Cristina Diniz Santos; Wanderson Duarte Penido; Gabriel de Menezes Yazbeck
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
